Annual report for Divi's Laboratories Ltd. for FY-2019
25-05-2019
Divis Laboratories Ltd - 532488 - Board Meeting Intimation for Consideration And Approval Of Standalone And Consolidated Audited Financial Results For The Year Ended 31St March 2019 And To Recommend Dividend, If Any, On Equity Shares For The Financial Year 2018-19.
DIVI''s LABORATORIES LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 25/05/2019 ,inter alia, to consider and approve standalone and consolidated audited financial results for the year ended 31st March 2019 and to recommend dividend, if any, on Equity Shares for the financial year 2018-19. As intimated earlier the Trading Window for dealing in securities of the Company has been closed from April 3, 2019 till 48 hours after the declaration of financial results as per the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.13-05-2019
DIVI'S LABORATORIES LTD. - 532488 - Format of Initial Disclosure to be made by an entity identified as a Large Corporate
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompayDIVI''S LABORATORIES LTD. 2CININE361B01024 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0 4Highest Credit Rating during the previous FY 0 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)Not Applicable 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkBSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: P V LAKSHMI RAJANI Designation: COMPANY SECRETARY EmailId: [email protected] Name of the Chief Financial Officer: L KISHORE BABU Designation: CHIEF FINANCIAL OFFICER EmailId: [email protected] Date: 24/04/2019 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets.24-04-2019
Divis Laboratories on strong growth trend, experts expect margins to expand
Strong demand for active ingredients is further accentuated by shortages even as prospects in custom synthesis business remain firm22-04-2019
DIVI'S LABORATORIES LTD. - 532488 - Compliance Certificate For Half Year Ended 31St March 2019 Under Regulation 40(10)
Compliance Certificate as required under Regulation 40(9) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, for the half year ended 31st March 2019.15-04-2019
DIVI'S LABORATORIES LTD. - 532488 - Shareholding for the Period Ended March 31, 2019
Divis Laboratories Ltd has submitted to BSE the Shareholding Pattern for the Period Ended March 31, 2019. For more details, kindly Click here10-04-2019
DIVI'S LABORATORIES LTD. - 532488 - Statement Of Investor Complaints For The Quarter Ended March 2019
No.of Investor complaints pending at the beginning of the quarter No.of Investor complaints received during the quarter No.of Investor complaints disposed of during the quarter No.of Investor complaints unresolved at the end of the quarter 0660 Name of the Signatory :- P.V.Lakshmi RajaniDesignation :- Company Secretary and Compliance Officer08-04-2019
DIVI'S LABORATORIES LTD. - 532488 - Compliance Certificate For Half Year Ended 31St March 2019
Compliance Certificate certifying compliance with the requirements of regulation 7(2), from the Company and the Registrar and Share Transfer Agent for half year ended 31st March 2019.04-04-2019
DIVI'S LABORATORIES LTD. - 532488 - Closure of Trading Window
Further to the NSE letter dated 02.04.2019 vide Ref No: NSE/CML/2019/11, we wish to inform you that the Trading Window for dealing in securities of the Company shall remain closed with immediate effect (i.e. April 03, 2019) till 48 hours after the declaration of financial results for the year ended 31st March, 2019 in terms of the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015.03-04-2019
DIVI'S LABORATORIES LTD. - 532488 - Announcement under Regulation 30 (LODR)-Code of Conduct under SEBI (PIT) Regulations, 2015
Pursuant to Regulation 8(2) of the SEBI (Prohibition of Insider Trading)Regulations, 2015, as amended, the Board approved the revised Code of Practices and Procedures for Fair Disclosure of Unpublished Price Sensitive Information (UPSI).28-03-2019